Using Posluma PET scan to monitor prostate cancer after treatment
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a special PET scan called Posluma can better monitor prostate cancer after treatment. It is for men with intermediate-risk cancer that has not yet spread, who are candidates for a targeted therapy approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer confirmed by a biopsy.
- Your cancer should be intermediate-risk and still contained within the prostate.
- Your doctor must think you are a good candidate for a treatment that targets only the tumor (focal therapy).
- You must be 18 years old or older.
- You must have a life expectancy of at least 10 years.
- You cannot have had any prior treatment for prostate cancer, like surgery, radiation, or hormone therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This study tests a new imaging scan (POSLUMA) that uses a radioactive tracer to find prostate cancer that has come back or spread after initial treatment. The scan may help doctors plan radiation therapy more accurately for men with recurrent prostate cancer.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
This trial tests a new type of PET scan to see how well it finds leftover cancer after you've had focal therapy (treatment to just part of the prostate) for intermediate-risk prostate cancer in the last 9 months.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.